WORCESTER, MA – Grove Instruments Inc., a medical device company based in Worcester, Massachusetts developing the world’s first noninvasive glucometer today announced that David Harlan, MD the William & Doris Krupp Professor of Medicine, Co-Director, Diabetes Center of Excellence, Director, Diabetes and Endocrinology Research Center and Chief, Diabetes Division, University of Massachusetts School of Medicine & UMass Memorial Health Care is joining the Company’s Scientific Advisory Board.
“We are continuing to build a world class Advisory Board to guide the development and clinical testing of our transformative noninvasive glucometer,” said Arthur Combs, CEO of Grove.
David joins Dr. Antoine Kaldany of the Harvard Medical Faculty Physicians and the Joslin clinic, Dr. Bill Tamborlane, the ADA’s outstanding Clinician in Diabetes 2010, as well as Dr. Craig Mello, world renowned molecular biologist and Nobel Laureate, whose passion for diabetes care emanates from personal family experience.
Since 1988, Dr. Harlan has practiced as a clinical and research diabetologist/endocrinologist with a major commitment to improving our understanding of the biology underlying diabetes and to developing better disease treatments. His efforts have ranged from epidemiological studies of patient outcomes following pancreas transplantation, to clinical trials (islet transplantation, immunotherapy trials, beta cell imaging, and efforts attempting to promote beta cell regeneration), to development of animal models in non-human primates or mice, to the cellular (studying pancreatic beta cells and the islet inflammatory infiltrate underlying T1D), and even to the molecular level (gene expression studies, promoter analyses, insulin splice forms). Dr. Harlan has been appointed to numerous leadership roles within the NIH (Chief, Diabetes Branch, NIDDK and before that a member of the NIDDK Advisory Council), the FDA, the American Diabetes Association, the Juvenile Diabetes Research Foundation, and other diabetes-interest groups. Since early 2010, he has served at the University of Massachusetts as a Co-Director of their recently established Diabetes Center of Excellence, Chief of the Diabetes Division and Director of the Diabetes Endocrinology Research Center. David’s top priority since joining UMass has been to build upon the University’s great tradition of basic diabetes research to achieve similar excellence in diabetes clinical care delivery and translational research.
“I’m the founding member of the David Harlan fan club. His expertise is a great addition to the Board,” commented Dr. Bill Tamborlane of Yale University and a current Grove Advisor. Dr. Antoine Kaldany of Harvard Medical Faculty and the Joslin Clinic noted “In the lab, Dr. Harlan is making major contributions to our understanding of the Islets of Langerhans and, as a clinical leader and educator, he is making equally important contributions to the care of people with diabetes.” Art Combs, Grove CEO said that “this is a particularly important time to have someone with Dr. Harlan’s credentials and experience advising the company. We’re thrilled to have David join the Advisory Board.”
About Grove Instruments
Grove Instruments, Inc. is a privately held pre-market medical device company developing the world’s first noninvasive glucometer with the potential to exceed the ISO standard for blood glucose meters. Grove’s patented technology is based on the seminal concept of the Optical Bridge and is unique among all NIR spectroscopic approaches to noninvasive blood glucose determination. The Company has been recognized for its innovation, technology development and clinical results on 10 separate occasions by the NIH NIDDK with funded SBIR Grants. In 2011, Grove was also recognized by the Massachusetts Life Sciences Center with an Accelerator Award – one of only 4 recipients out of all Boston-area life sciences companies applying in that round. For more information see www.groveinstruments.com or contact Arthur Combs (314 341 3444 mobile).
